You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 [see all tables in this series...]

Part (viii) Percentage amongst all clients with hypnotics and sedatives as primary drug

Country		Inject	Smoke/inhale	Eat/drink	Sniff	Others	Base (known status)	Status unknown
Bulgaria		0.0	0.0	100.0	0.0	0.0	5	0
Czech Republic		0.0	0.0	100.0	0.0	0.0	23	0
Denmark		1.7	1.7	96.6	0.0	0.0	58	13
Germany		5.2	1.7	85.8	0.7	6.7	3410	3717
Ireland		0.0	0.0	100.0	0.0	0.0	60	2
Greece		0.0	4.2	95.8	0.0	0.0	24	1
Spain	(1)	0.0	1.3	98.2	0.4	0.0	672	8
France		1.9	1.9	89.4	4.3	2.5	322	122
Italy		6.8	1.9	71.2	0.0	20.1	309	0
Cyprus		0.0	0.0	100.0	0.0	0.0	2	0
Lithuania		35.0	0.0	65.0	0.0	0.0	80	4
Luxembourg		0.0	0.0	100.0	0.0	0.0	4	0
Hungary		2.2	2.4	95.4	0.0	0.0	851	0
Malta		0.0	0.0	100.0	0.0	0.0	2	1
Netherlands	(2)	0.0	2.4	96.3	1.2	0.0	164	20
Slovakia		0.0	0.0	100.0	0.0	0.0	11	0
Finland		3.0	1.5	95.5	0.0	0.0	133	3
Sweden		0.0	0.5	99.5	0.0	0.0	196	3
United Kingdom	(3)	0.8	1.2	90.9	0.3	6.7	2138	287
Total		3.2	1.6	89.4	0.6	5.2	8464	4181

Notes:

Only countries where there are clients reported with hypnotics and sedatives as primary drug are shown.

(1) Data from Spain refer to 2004.

(2) Data refer to outpatient treatment centres and low-threshold agencies.

(3) Data refer to collection period between 01.04.2004 and 31.03.2005.

See also 'Table TDI-110' for cocaine CIH and crack route of administration distribution, and 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports - TDI - outpatient treatment centres.